Every Form 4 that Amneal Pharmaceuticals Inc (AMRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRX filings page.
Amneal Pharmaceuticals, Inc. (AMRX) insider Andrew S. Boyer, an Executive Vice President, reported a bona fide gift of 80,000 shares of Class A Common Stock on September 1, 2026. The gift was made to a trust for the benefit of certain family members, and Boyer is not the trustee. Following this transfer, he reports 193,646 shares of direct holdings. No Rule 10b5-1 trading plan is reported for this transaction.
Amneal Pharmaceuticals, Inc. (AMRX) reported that Executive Vice President Andrew S. Boyer made a bona fide gift of 152,426 shares of Class A Common Stock on 2026-08-21. The shares were gifted to a trust for the benefit of certain family members, where Boyer does not serve as trustee. Following this transfer, Boyer’s reported direct holdings are 273,646 shares of Class A Common Stock.
Amneal Pharmaceuticals director John Kiely reported two transactions in Class A Common Stock on 2026-08-13. He sold 50,000 shares at a weighted average price of $17.64 per share in multiple trades within a $17.26–$17.88 range, and separately donated 10,000 shares as a charitable gift to a donor advised fund.
Amneal Pharmaceuticals, Inc. Executive Vice President Nikita Shah reported a sale of 146,403 shares of Class A Common Stock on August 12, 2026. The sale was executed at a weighted average price of $17.51 per share, with individual trade prices ranging from $17.40 to $17.67 per share. Following this transaction, Shah directly holds 253,390 shares of Amneal Class A Common Stock.
Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported selling a total of 216,613 shares of Class A Common Stock in two open-market or private transactions. On 2026-08-12 he sold 210,000 shares at $17.40 per share (weighted average, with individual trades between $17.25 and $17.67). On 2026-08-11 he sold 6,613 shares at $17.70 per share (weighted average, with individual trades between $17.65 and $17.73). The Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan, and post-transaction share holdings were not reported in this form.
BUCHI J KEVIN reported disposition transactions in this Form 4 filing.
Amneal Pharmaceuticals, Inc. director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on 2026-08-11 at a weighted average price of $17.18 per share. According to the footnote, the shares were sold in multiple trades between $17.07 and $17.31 per share. Following this activity, 93,499 shares are held indirectly by a trust and a separate holding entry shows 75,077 shares held directly.
Amneal Pharmaceuticals, Inc. reported that reporting person Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 shares of Amneal Class A common stock. The shares are held through limited liability companies controlled by family trusts.
The acquisition occurred on August 10, 2026 as part of Amneal’s purchase of 100% of Kashiv BioSciences, LLC membership interests. Deal consideration included $375,000,000 in cash (subject to purchase price adjustments) and 28,942,098 Amneal Class A shares. Following this transaction, entities associated with Patel held 61,341,678 Class A shares indirectly.
Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026. This equity was received as part of Amneal’s acquisition of Kashiv BioSciences, LLC, alongside cash consideration and other share issuances. Following this transaction, Patel also holds 1,388,521 shares directly and 24,753,252 shares indirectly through family trusts.
Amneal Pharmaceuticals, Inc. director Gautam Patel reported an indirect acquisition of 283,632 shares of Class A common stock on August 10, 2026. The shares were received by limited liability companies managed by him as part of Amneal’s acquisition of Kashiv BioSciences, LLC. Following this transaction, he also reported 1,643,963 shares held directly.
Amneal Pharmaceuticals, Inc. reported that President & Co-CEO Chirag K. Patel, through limited liability companies he manages, acquired 6,381,734 shares of Class A common stock on August 10, 2026. These shares were issued as part of Amneal’s acquisition of Kashiv BioSciences, LLC. After the transactions, Patel is reported as holding 1,393,470 shares directly and additional Class A shares indirectly, including 21,269,420 shares held by family trusts.
Amneal Pharmaceuticals director Deborah M. Autor reported an open-market sale of Class A Common Stock. On May 11, 2026, she sold 34,819 shares at a weighted average price of $12.94 per share in multiple trades between $12.75 and $13.27. Following the sale, she directly holds 93,660 shares.
Amneal Pharmaceuticals director J. Kevin Buchi reported routine equity compensation moves. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common shares at no cash cost, bringing his direct holdings to 75,077 shares.
On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one Class A share. A separate trust associated with him holds 262,072 Class A shares indirectly. The filing shows no open-market stock purchases or sales.
Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake through equity compensation activity. On May 7, 2026, 34,819 restricted stock units were converted into 34,819 shares of Class A Common Stock, reflecting an exercise of derivative securities. Following this settlement, she directly held 128,479 Class A shares. On May 6, 2026, she was also credited with 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, adding to her unvested equity awards.
Amneal Pharmaceuticals director Jeffrey P. George reported routine equity compensation activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares and bringing his direct holdings to 344,614 shares.
These 34,819 restricted stock units were previously granted and each unit represented a right to receive one share of Class A Common Stock upon vesting. On May 6, 2026, he was also awarded 19,824 new restricted stock units, which will convert into Class A shares when they vest under the company’s standard vesting schedule tied to the annual meeting and one‑year anniversary of grant.
Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock at a stated price of $0.00 per share. After this exercise, he directly owned 1,643,963 shares of Class A Common Stock. On May 6, 2026, he was also granted 19,824 restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, which vest under the company’s director vesting schedule linked to the first annual meeting and one-year anniversary of grant.
Amneal Pharmaceuticals director John Kiely reported compensation-related equity activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a stated price of $0.00 per share. The Form 4 also shows a grant of 19,824 restricted stock units on May 6, 2026, each representing a right to receive one share of Class A Common Stock. After these transactions, Kiely directly owns 260,252 Class A Common Stock shares, with no remaining restricted stock units reported in this filing.
Amneal Pharmaceuticals director Ted C. Nark increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a price of $0 per share, bringing his direct holdings to 325,848 shares.
The exercised units were part of a 34,819-unit award granted on May 6, 2025 that vested on May 7, 2026. On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one share of Class A Common Stock, with vesting tied to the company’s director vesting schedule.
Amneal Pharmaceuticals director Paul M. Meister reported equity compensation moves involving the company’s Class A Common Stock. On May 7, 2026, he exercised 48,747 Restricted Stock Units, receiving the same number of Class A shares, bringing his direct holdings to 832,800 shares.
Separately, on May 6, 2026, he received a new grant of 30,837 Restricted Stock Units, each representing a contingent right to one share of Class A Common Stock. A footnote states an earlier grant of 48,747 RSUs on May 6, 2025 vested on May 7, 2026.
Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake through stock-based compensation activity. He exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock and did not sell any shares. Following this exercise, he directly owns 320,804 shares. In a separate transaction, he also received a grant of 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock.
Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that Co-CEO Chintu Patel received a grant of 544,663 performance-based restricted stock units, each tied to one share of Class A common stock. The award vests based on the stock achieving specified average closing price targets over a three-year performance period.
The number of shares ultimately earned can range from 0% to 200% of the target amount, depending on performance. Any earned units are scheduled to vest in full on February 28, 2029. This is a compensation grant at no cash cost per unit, not an open-market purchase or sale.
Amneal Pharmaceuticals President & Co-CEO Chirag K. Patel received a grant of 544,663 performance-based restricted stock units tied to Class A common stock. These units do not involve a cash purchase and represent a compensation award that can convert into shares in the future.
The award is based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The number of shares ultimately earned can range from 0% to 200% of the 544,663 target, with the table reflecting the maximum shares potentially issuable. Any units that are earned will vest in full on February 28, 2029, at the end of the performance period.
Amneal Pharmaceuticals, Inc. director and Co-CEO Chintu Patel reported vesting and settlement of several equity awards into Class A Common Stock. On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, deemed earned and vested, and settled into shares on a one-for-one basis. Time-based restricted stock units also vested and were settled into Class A shares.
The gross shares issued from these vestings were partly withheld to cover tax withholding obligations, with multiple Form 4 code “F” transactions showing Class A shares withheld at $13.31 and $13.30 per share for taxes. After these transactions, Patel directly holds 1,388,521 shares of Class A Common Stock and 185,185 restricted stock units, and indirectly holds 24,753,252 Class A shares through family trusts.
Amneal Pharmaceuticals, Inc. President & Co-CEO Chirag K. Patel reported multiple equity award vestings and related share movements. On March 3, 2026, performance-based restricted stock units covering 733,944 units vested after achieving a performance threshold that resulted in vesting of 200% of the targeted number, and were settled into the same number of Class A Common shares on a one-for-one basis. Additional restricted stock units covering 59,931 units also converted into Class A Common Stock.
To cover tax withholding obligations from these vestings, the reporting person disposed of 297,537 and 15,616 Class A shares at per-share prices of $13.31, and on March 4, 2026 disposed of a further 37,825 Class A shares at $13.30, all characterized as share withholding rather than open-market sales. After these transactions, direct holdings reported include 1,393,470 shares of Class A Common Stock and 185,185 restricted stock units, with an additional 21,269,420 Class A shares held indirectly through family trusts.
Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported multiple equity award vestings and related share movements in Class A Common Stock and restricted stock units.
On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, resulting in the vesting and settlement of 305,810 performance-based restricted stock units into an equal number of Class A Common Stock shares on a one-for-one basis, with a portion of the resulting shares withheld to satisfy tax obligations. Additional time-based restricted stock units granted on March 3, 2022, March 3, 2023, March 4, 2024 and March 3, 2025 vested in scheduled installments and were converted into Class A Common Stock, again with some shares withheld for taxes.
Following these transactions, Daly held 251,784 shares of Class A Common Stock directly as of March 4, 2026, along with 71,760 restricted stock units, reflecting ongoing equity-based compensation rather than open-market purchases or sales.
Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported multiple equity award vestings and related share issuances. On March 3 and 4, 2026, restricted stock units and performance-based restricted stock units were exercised and converted into shares of Class A Common Stock at no exercise price.
A performance-based grant of 458,716 performance-based restricted stock units from a March 3, 2023 award vested at 200% of its targeted amount after share-price conditions were met and was settled one-for-one into Class A shares. Across the transactions, portions of the newly issued shares, including amounts such as 229,817 shares at $13.31 and other blocks at prices around $13.30–$13.31, were withheld to cover tax withholding obligations, rather than sold in open-market trades. Following these events, Konidaris directly held 449,434 shares of Class A Common Stock as of the latest reported transaction.
Amneal Pharmaceuticals, Inc. Executive Vice President Andrew S. Boyer reported multiple equity award vestings and related share transfers. On March 3, 2026, performance-based restricted stock units, including 397,554 performance-based RSUs, were certified as having met their performance threshold and vested, then settled into an equal number of Class A Common Stock shares on a one-for-one basis. Several time-based restricted stock unit grants also vested and were settled into Class A Common Stock.
To cover tax withholding obligations tied to these vestings, Boyer had blocks of Class A Common Stock withheld, including 199,175 shares at $13.31 per share and 19,136 shares at $13.30 per share, classified as tax-withholding dispositions. Following the transactions on March 4, 2026, Boyer directly held 426,072 shares of Amneal Class A Common Stock.
Amneal Pharmaceuticals Executive Vice President Nikita Shah reported multiple equity award vestings and related share withholdings. On March 3, 2026, performance-based restricted stock units granted in 2023 were certified above target, vesting at 200% of the targeted number and settling into an equal number of Class A shares.
Across March 3–4, 2026, Shah acquired Class A Common Stock through exercises and conversions of restricted stock units and performance-based units, while a portion of the resulting shares was automatically disposed of at prices around $13.30 per share to satisfy tax withholding obligations.
Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Co-CEO Chintu Patel reported equity awards of restricted stock units. On March 2, 2026, he received 190,632 restricted stock units, each representing a contingent right to one share of Class A common stock, vesting in four equal annual installments beginning March 2, 2027.
He was also granted 354,031 performance-based restricted stock units tied to average closing price targets over a three-year performance period. The award can pay out from 0% to 200% of the 354,031 target shares, with any earned units vesting in full on February 28, 2029, representing the maximum number of shares issuable under this grant.
Patel Chirag K. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that President and Co-CEO Chirag K. Patel received equity awards in the form of restricted stock units. He was granted 190,632 time-based restricted stock units, each representing a right to receive one share of Class A common stock, vesting in four equal annual installments beginning on March 2, 2027.
He also received 354,031 performance-based restricted stock units, tied to the company’s average closing share price over a three-year performance period. The number of shares ultimately delivered may range from 0% to 200% of the target, with any earned units vesting in full on February 28, 2029, and the table reflecting the maximum shares issuable.
Shah Nikita reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Nikita Shah received equity awards in the form of restricted stock units. She was granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units, each representing a right to receive one share of Class A common stock.
The time-based units vest in four equal annual installments starting on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year performance period, with potential payout from 0% to 200% of the target, and any earned units vesting on February 28, 2029.
Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported equity awards of restricted stock units. He acquired 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units, each representing a contingent right to receive one share of Amneal’s Class A common stock.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based restricted stock units are tied to Amneal’s average closing share price over a three-year performance period and can pay out from 0% to 200% of the 72,622 target shares, with any earned units vesting in full on February 28, 2029.
Daly Jason B. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that EVP and Chief Legal Officer Jason B. Daly received two equity awards on March 2, 2026. He was granted 65,359 restricted stock units that vest in four equal annual installments beginning March 2, 2027. He also received 65,359 performance-based restricted stock units tied to three-year stock price targets, with any earned units vesting on February 28, 2029.
BOYER ANDREW S reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer reported awards of 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Class A common stock if vesting conditions are met.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year period ending February 28, 2029, with payout ranging from 0% to 200% of a 65,359-share target and a maximum of 65,359 shares issuable under the award.
Amneal Pharmaceuticals, Inc. filed a Form 4 showing a share sale by one of its directors. On 11/17/2025, the reporting person sold 50,000 shares of Amneal Class A common stock in an open-market transaction coded "S" for sale. The weighted average sale price was $11.72 per share, with individual trades executed between $11.70 and $11.75 per share.
After this transaction, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock in direct ownership form. The filing notes that full details of the individual trade prices within the reported range are available upon request.
Amneal Pharmaceuticals, Inc. (AMRX) reported insider activity by its Executive Vice President. On November 12, 2025, the officer exercised stock options for 36,331 and 95,525 shares at an exercise price of $2.75 per share and sold 131,856 Class A shares at a $11.92 weighted average price.
The sale occurred across multiple trades between $11.85 and $12.02 per share. Following these transactions, the reporting person directly beneficially owned 146,403 shares. The reported option grants (fully vested) show 0 derivative securities remaining after exercise, with prior expirations listed as May 7, 2028 and March 1, 2029.